[荧光原位杂交法对多发性骨髓瘤患者分子变化的研究]
[Investigation of the molecular changes in patients with multiple myeloma by fluorescence in situ hybridization].
作者信息
Yang Rui-fang, Li Chun-ming, Chen Li-juan, Qiu Hai-rong, Yang Hui, Liu Peng, Xu Jia-ren, Li Jian-yong
机构信息
Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Provincial Hospital, Nanjing, Jiangsu, P.R. China.
出版信息
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2010 Oct;27(5):567-70. doi: 10.3760/cma.j.issn.1003-9406.2010.05.020.
OBJECTIVE
To investigate the incidence and prognosis of 1q21 amplification, 13q14 deletion, TP53 gene deletion and IgH translocation in patients with multiple myeloma (MM).
METHODS
Interphase fluorescence in situ hybridization (I-FISH) with four different specific probes for the regions containing 1q21, 13q14.3 (D13S319), 14q32 and TP53 gene were performed in 43 MM patients.
RESULTS
Among the 43 MM patients, 1q21 amplification was observed in 28 (65.1%) cases, 13q14 deletion in 30 (69.7%) cases, TP53 gene deletion in 8 (18.6%) cases, and IgH translocation in 29 (67.4%) cases. The mortality of MM patients with 1q21 amplification, 13q14 deletion or TP53 gene deletion was higher than those without them.
CONCLUSION
There is high frequency of 1q21 amplification, 13q14 deletion, TP53 gene deletion and IgH translocation in multiple myeloma, and 1q21 amplification, 13q14 deletion and TP53 gene deletion are poor prognosis factors for MM patients.
目的
探讨多发性骨髓瘤（MM）患者中1q21扩增、13q14缺失、TP53基因缺失及IgH易位的发生率及预后情况。
方法
对43例MM患者进行间期荧光原位杂交（I-FISH），采用四种不同的特异性探针检测包含1q21、13q14.3（D13S319）、14q32及TP53基因的区域。
结果
43例MM患者中，28例（65.1%）观察到1q21扩增，30例（69.7%）观察到13q14缺失，8例（18.6%）观察到TP53基因缺失，29例（67.4%）观察到IgH易位。存在1q21扩增、13q14缺失或TP53基因缺失的MM患者死亡率高于无这些情况的患者。
结论
多发性骨髓瘤中1q21扩增、13q14缺失、TP53基因缺失及IgH易位发生率较高，且1q21扩增、13q14缺失及TP53基因缺失是MM患者预后不良的因素。
Zotero 插件